Top 5 Urology Times genomic testing articles of 2025

The field of genomic testing continued to advance in 2025, as shown by Urology Times’ top content in this area. The highlights range from the launch of a new genetic test for prostate cancer as well as data indicating genomic testing’s role in helping with treatment intensification decisions in prostate cancer.

PROSTOX ultra launches on US market following new data presented at ASTRO 2025

The PROSTOX ultra genetic test is now commercially available in the US for use in predicting which patients with localized prostate cancer are at higher risk of developing late genitourinary toxicity from stereotactic body radiotherapy, MiraDx announced in a news release. The test was previously available through an Early Access Program at select academic centers and private practices.¹

Genomic testing helps inform treatment intensity decisions in intermediate-risk prostate cancer

Data from a large, real-world analysis presented at the American Society for Radiation Oncology 67th Annual Meeting suggest that treatment can be deintensified for many patients with intermediate-risk prostate cancer. Drawing on genomic biomarker test results across more than 60,000 patients, the study highlights how genetic testing can refine risk stratification and guide decisions between active surveillance, single-modality therapy, and intensified multimodal approaches.² In an interview with Urology Times, presenting author Christopher Lee, MD, breaks down this study's implications and future directions.

Study: Referral rates for genetic counseling in renal cell carcinoma remain low

Although national guidelines recommend genetic counseling for all patients with early-onset or bilateral renal cell carcinoma, the referral rate remains low, according to recent findings published in Urologic Oncology.³ These findings have profound implications, as genetic evaluation can inform treatment decisions for kidney cancer and determine risks for other malignancies. Senior author of the study, Hong Truong, MD, MS, sat down with Urology Times to outline key findings and implications from the study.

Decipher test is predictive of chemotherapy benefit in metastatic prostate cancer

Data published in Cell indicate that the Decipher Prostate Genomic Classifier can predict which patients with metastatic prostate cancer will benefit from treatment intensification with the chemotherapy docetaxel.⁴

Veda Giri, MD, outlines recent review on germline testing in prostate cancer

In a recent video interview with Urology Times, Veda N. Giri, MD, outlined key points addressed in her recent review on the current state of germline testing in prostate cancer.⁵ “We wanted to make sure we were touching upon 3 areas: laying the groundwork [by discussing] what the guidelines are, how we can think about implementation strategies that are traditional or more alternative but responsibly done, and then third, thinking about this for reducing disparities,” Giri explained.

REFERENCES

1. MiraDx announces the commercial availability of PROSTOX™ ultra for prediction of risk of late genitourinary toxicity in prostate cancer patients considering radiation therapy. News release. MiraDx. October 2, 2025. Accessed December 18, 2025. https://miradx.com/prostox-commerically-available/

2. Lee CM. Genomic tumor testing in NCCN favorable and unfavorable intermediate-risk prostate cancer informs treatment intensity: data from an open access research registry. Presented at: American Society of Radiation Oncology 67th Annual Meeting; September 27-October 1, 2025; San Francisco, CA. Abstract 3266.

3. Makarova E, Bakhl K, Demirsoy S, et al. Utilization of genetic evaluation in patients with kidney cancer who meet guidelines for genetic referral. Urol Oncol. 2025:S1078-1439(25)00238-8. doi:10.1016/j.urolonc.2025.06.00

4. Grist E, Dutey-Magni P, Parry MA, et al. Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers. Cell. 2025. doi:10.1016/j.cell.2025.07.042

5. Loeb S, Vadaparampil ST, Giri VN. Germline testing for prostate cancer: current state and opportunities for enhanced access. EBioMedicine. 2025:116:105705. doi:10.1016/j.ebiom.2025.105705